Hexamethylmelamine

This page contains recent news articles, when available, and an overview of Hexamethylmelamine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Recurrent Low-Grade Carcinoma of the Ovary Less Responsive to …  -  Mar 10, 2008
...such as liposomal doxorubicin; topotecan; hexamethylmelamine; oral VP-16; xeloda and gemcitabine. One patient had a partial response to paclitaxel. ... newswise.com

Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating...  -  Jan 29, 2007
...including topotecan, anthracyclines such as doxorubicin, gemcitabine, cyclophosphamide, vinorelbine, hexamethylmelamine, ifosfamide, and etoposide. ... Free with registration - PR Newswire - AccessMyLibrary.com

Chemotherapy affects executive function, verbal memory.(Clinical …  -  Feb 15, 2005
Cognitive or Motor Impairment L-asparagine Busulfan Hexamethylmelamine Procarbazine Thiotepa * Also associated with cognitive impairment individually. ... Free with registration - Family Practice News - AccessMyLibrary.com

Gemzar The New Drug For Recurrent Ovarian Cancer  -  Jan 13, 2007
Additional possibilities are Melphalan, Hexamethylmelamine, 5FU (including Xeloda), Oxaliplatin, Gemcitabine + Oxaliplatin, Vinorelbine + Oxaliplatin, ... Medical News Today - Medical News Today (press release)

Detailed Guide: Ovarian Cancer  -  Jan 19, 2008
...(Adriamycin) and liposomal doxorubicin (Doxil), gemcitabine, cyclophosphamide, vinorelbine (Navelbine), hexamethylmelamine, ifosfamide, and etoposide. ... ACS News Center

Recurrent Low-grade Carcinoma Of The Ovary Less Responsive To …  -  Mar 13, 2008
...such as liposomal doxorubicin; topotecan; hexamethylmelamine; oral VP-16; xeloda and gemcitabine. One patient had a partial response to paclitaxel. ... sciencedaily.com

Press Release: Threshold Pharmaceuticals Initiates Phase 2 Clinical...  -  Jan 29, 2007
...including topotecan, anthracyclines such as doxorubicin, gemcitabine, cyclophosphamide, vinorelbine, hexamethylmelamine, ifosfamide, and etoposide. ... Pay-Per-View - PR Newswire - HighBeam Research

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.